Stockreport

Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]

Avidity Biosciences, Inc.  (RNA) 
PDF peak-revenue prospects for its cancer drugs Kisqali and Scemblix to offset losses from expiring patents. In a statement ahead of an investor event, the company lifted [Read more]